Go Back

CLSI reporting update for Ceftriaxone, Cefotaxime, Ceftazidime

19 May 2024

Do not report for Enterobacter cloacae complex, Klebsiella aerogenes, Citrobacter freundii

By: Tish Gross, laboratory and imaging outreach supervisor

New information from Clinical and Laboratory Standards Institute (CLSI) has indicated the importance of not reporting Ceftriaxone, Cefotaxime and Ceftazidime for all Enterobacter cloacae complex, Klebsiella aerogenes and Citrobacter freundii.

IDSA (Infectious Diseases Society of America) recognizes these three organisms as the most common Enterobacterales at moderate to high risk for clinically significant AmpC production. Salem Health Laboratories’ instrumentation cannot distinguish between AmpC and ESBL for these organisms, so we have elected to suppress them. Cefipime will be visible.

IDSA suggests that patients with uncomplicated cystitis due to one of the listed bacteria may still be considered for ceftriaxone therapy, if sensitivity is known.

Questions? Call Microbiology 503-814-1662 or email